Use of the dTAG system <i>in vivo</i> to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilities
Paul Yenerall(Pfizer (United States)), Wenyue Hu(Beijing University of Chinese Medicine)
Cited by 15
Related Papers
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)
|Journal of Medicinal Chemistry|2017|128
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
|Journal of Medicinal Chemistry|2011|69
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
|Journal of Medicinal Chemistry|2016|69
Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.
|Molecular Cancer Therapeutics|2013|4
CCDC 1982336: Experimental Crystal Structure Determination
|The Cambridge Structural Database|2020|0